Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 5,501–5,600 of 10,906
mRNA vaccines against infectious diseases and future direction
Aleem, M. T., Munir, F., Shakoor, A., & Gao, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112320 · Cited by 13
Impact of the COVID-19 pandemic on uveitis patient care
Vu, A. F., Kodati, S., Lin, P., Bodaghi, B., & Emami-Naeini, P. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-320368 · Cited by 8
Frahm, N., Fneish, F., Ellenberger, D., Haas, J., Löbermann, M., Peters, M., Pöhlau, D., Röper, A.-L., Schilling, S., Stahmann, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113640 · Cited by 10
Nanomedicines via the pulmonary route: a promising strategy to reach the target?
Guérin, M., & Lepeltier, É. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01590-1 · Cited by 10
Schreiber, K. I., Graversgaard, C., Petersen, R., Jakobsen, H., Bojesen, A. B., Krogh, N. S., Glintborg, B., Hetland, M. L., & Hendricks, O. (2021) · Vaccines · doi:10.3390/vaccines10010035 · Cited by 8
Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
Kim, S., & Seok, H. Y. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06676-1 · Cited by 10
Zimmer, D. N., Schmid, F., & Settanni, G. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c05057 · Cited by 12
Rane, M. S., Robertson, M. M., Kulkarni, S., Frogel, D., Gainus, C., & Nash, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.039 · Cited by 8
A case of psoriatic spondyloarthritis exacerbation triggered by COVID‐19 messenger RNA vaccine
Ohmura, S., Hanai, S., Ishihara, R., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18013 · Cited by 8
Saá, P., Fink, R. V., Dawar, H., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad253 · Cited by 8
Nosocomial COVID‐19 infection in the era of vaccination and antiviral therapy
McNeil, T., Zhang, F., Moffatt, S., Emeto, T. I., & Tucker, E. C. (2023) · Internal Medicine Journal · doi:10.1111/imj.16298 · Cited by 8
Hannawi, S., Wu, X.-H., Villalobos, R. E., Burhan, E., Lallaine Borra, M. D., Gupta, R. K., Aquitania, G. P., Ang, B. W. C., Mae A. Zabat, G., Roa, C. C., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.013 · Cited by 8
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination
Pilotto, A., Catania, M., Mattioli, I., Zoppi, N., Ceccardi, G., Rao, R., Gipponi, S., Magoni, M., Gamba, M., & Padovani, A. (2024) · European Journal of Neurology · doi:10.1111/ene.16191 · Cited by 9
Schulte, B., Marx, B., Korencak, M., Emmert, D., Aldabbagh, S., Eis‐Hübinger, A. M., & Streeck, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704719 · Cited by 8
O’Reilly, S. R., Byrne, J., Feeney, E. R., Mallon, P. W. G., & Gautier, V. (2024) · Vaccines · doi:10.3390/vaccines12101089 · Cited by 11
Yasmin, S., Ansari, M. Y., Pandey, K., & Dikhit, M. R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130754 · Cited by 8
mRNA-1273 is placenta-permeable and immunogenic in the fetus
Chen, J., Hsu, M., Kuo, R., Wang, L., Kuo, M., Tseng, L.-Y., Chang, H., & Chiu, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102489 · Cited by 10
Pityriasis Rubra Pilaris After Moderna COVID-19 Vaccination: A Case Report and Literature Review
Liu, Y. A., Dai, J., Nagarajan, P., et al. (2023) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002369 · Cited by 8
Filon, F. L., Lazzarato, I., Patriarca, E., Iavernig, T., Peratoner, A., Perri, G., Ponis, G., Rocco, G., & Cegolon, L. (2022) · Vaccines · doi:10.3390/vaccines10101616 · Cited by 9
Killeen, T., Saxer, R. T., & Kermer, V. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00652-y · Cited by 9
Kuzmina, A., Korovin, D., Cohen-Lass, I., Atari, N., Ottolenghi, A., Hu, P., Mandelboim, M., Rosental, B., Rosenberg, E., Diaz‐Griffero, F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16750 · Cited by 8
Zhu, G., Yang, Y., & Sun, T. (2022) · Biomaterials Science · doi:10.1039/d2bm00011c · Cited by 8
Waldman, S., Adams, J. Y., Albertson, T. E., Juarez, M. M., Myers, S. L., Atreja, A., Batra, S., Foster, E. E., Huynh, C. V., Liu, A. Y., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.336 · Cited by 9
Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., Santiaguel, J., Frias, M. V., Miyakis, S., Alves de Mesquita, M., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2408863 · Cited by 8
Self-citationEslait-Olaciregui, S., Llinás-Caballero, K., Patiño-Manjarrés, D., Urbina, T., Cediel-Becerra, J.-F., & Domínguez-Domínguez, C. A. (2023) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231165674 · Cited by 14
Boikova, A., Quaife-Ryan, G. A., Batho, C. A. P., Lawrence, E., Robinson, H., Ascanelli, C., Jennbacken, K., Wang, Q., Hansson, K. M., Seaton, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.02.551469 · Cited by 7
A single immunization with cellular vaccine confers dual protection against SARS‐CoV ‐2 and cancer
Shimizu, K., Ueda, S., Kawamura, M., Satoh, M., & Fujii, S. (2022) · Cancer Science · doi:10.1111/cas.15434 · Cited by 7
What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021
Abramczyk, U., & Kuzan, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051022 · Cited by 8
Zhang, Y., Clarke, S. P., Wu, H., Li, W., Zhou, C. S., Lin, K., Wang, J., Wang, J., Liang, Y., Wang, X., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28776 · Cited by 9
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Zyoud, S. H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01254-3 · Cited by 11
Hidayat, R., Mustika, A. P., Avisha, F., Djuliannisaa, Z., Winari, D. D., Putri, R. A., Lisman, H. M., Davin, V., Widhani, A., Aini, M. H., et al. (2022) · Vaccines · doi:10.3390/vaccines10060877 · Cited by 9
Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
Chang, J., Chiou, J., Hung, C.-S., Liu, M.-C. J., Chang, H., Hong, S., Wang, C.-Y., Lin, Y., Hsieh, Y., Chung, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10020312 · Cited by 8
Yang, H., Gao, Z., Zhou, Y., Ge, X., Pan, X., Li, J., Zhang, Z., Jin, X., Liu, G., He, Z., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113892 · Cited by 13
Luan, N., Wang, Y., Cao, H., Lin, K., & Liu, C. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27637 · Cited by 8
Shapiro, L. C., Thakkar, A., Gali, R., Gonzalez‐Lugo, J. D., Bazarbachi, A. H., Rahman, S., Pradhan, K., Fehn, K., Abreu, M., Kornblum, N. S., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2074988 · Cited by 8
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8
Li, H., Cai, D., Jiang, D., Li, X., Liao, X., Liu, D., Liu, Z., Zhu, P., Yin, G., Ming, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28434 · Cited by 7
Albayat, S. S., Almaslamani, M., Al‐Romaihi, H. E., Khogali, H., Mundodan, J. M., Joury, J., & Haridy, H. (2023) · Vaccines · doi:10.3390/vaccines11050953 · Cited by 11
So, B., & Kwon, K. H. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2052467 · Cited by 11
Shafrir, A., Amer, J., Hakimian, D., Milgrom, Y., Massarwa, M., Hazou, W., Imam, A., Khalaileh, A., & Safadi, R. (2022) · Hepatology Communications · doi:10.1002/hep4.1901 · Cited by 8
Enfermedad por coronavirus 2019 (COVID-19)
Ochoa, J. E. S., & Cueto, M. C. S. (2021) · Medicina UPB · doi:10.18566/medupb.v40n2.a06 · Cited by 13
Control, Exogeneity, and Directness: Understanding and Designing Quasi- and Natural Experiments
Remler, D. K., & Ryzin, G. G. V. (2024) · American Journal of Evaluation · doi:10.1177/10982140241265708 · Cited by 11
Statistical mechanics study of the introduction of a vaccine against COVID-19 disease
De-Leon, H., & Pederiva, F. (2021) · Physical review. E · doi:10.1103/physreve.104.014132 · Cited by 9
Santi, T., Sungono, V., Kamarga, L., Samakto, B. D., Hidayat, F., Hidayat, F. K., Satolom, M., Permana, A., Yusuf, I., Suriapranata, I. M., et al. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.209 · Cited by 10
‘COVID vaccine arm’ may present after both mRNA vaccines vaccination
Gregoriou, S., Kleidona, I. A., Tsimpidakis, A., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17614 · Cited by 8
Chou, S., Chang, Y., Liao, C., Chen, T., Sun, K.-J., Huang, W., & Wu, Y. (2022) · Platelets · doi:10.1080/09537104.2022.2042237 · Cited by 8
Abebe, E. C., Ayele, T. M., Muche, Z. T., Mariam, A. B. T., Baye, N. D., Agidew, M. M., & Dejenie, T. A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2104059 · Cited by 10
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context
Ruschig, M., & Marschall, A. L. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00580-y · Cited by 10
A controlled effects approach to assessing immune correlates of protection
Gilbert, P. B., Fong, Y., Kenny, A., & Carone, M. (2022) · Biostatistics · doi:10.1093/biostatistics/kxac24 · Cited by 36
Self-citationJeantin, L., Abdi, B., Soulié, C., Sterlin, D., Maillart, É., Beigneux, Y., Hippolyte, A., Belin, L., Marcelin, A., Pourcher, V., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331770 · Cited by 8
Zhang, Y., Li, J., Wang, Z., Kuang, Y., Li, S., & Wang, X. (2025) · Animal Diseases · doi:10.1186/s44149-025-00186-7 · Cited by 9
“…the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines were developed from sequence design to clinical approval approximately 10 months during the global COVID-19 pandemic, marking a historic milestone in the advancement of mRNA vaccine technology (Polack et al. 2020; Baden et al. 2021).”
Robinson, A. G., Mazurek, A., Xu, M., & Gong, Y. (2021) · Current Oncology · doi:10.3390/curroncol29010006 · Cited by 8
Long Non-coding RNA Based Therapy for Cardiovascular Disease
Quinones, N. B., Belluomo, R., Juni, R. P., & Boon, R. A. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10686-z · Cited by 13
Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study
Palaia, I., Caruso, G., Donato, V. D., Vestri, A., Napoli, A., Perniola, G., Casinelli, M., Fegatelli, D. A., Campagna, R., Tomao, F., et al. (2021) · Vaccines · doi:10.3390/vaccines10010012 · Cited by 8
Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma
Gilchuk, P., Thomsen, I. P., Yoder, S. M., Brady, E. J., Chappell, J. D., Stevens, L. J., Denison, M. R., Sutton, R. E., Chen, R. E., VanBlargan, L. A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103602 · Cited by 7
Pham, K., Torres, H. M., Satlin, M. J., et al. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab014 · Cited by 8
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Fang, Z., Peng, L., Lucas, C. G. D. O., Lin, Q., Zhou, L., Yang, L., Feng, Y., Ren, P., Renauer, P. A., Monteiro, V. S., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00435-w · Cited by 7
Sung, S., Jenny, L. A., Chang, Y., Wang, N., & Liu, P. (2023) · Vaccines · doi:10.3390/vaccines11020365 · Cited by 9
Reactivation of a BCG Vaccination Scar Following the First Dose of the Moderna COVID-19 Vaccine
Tao, T. (2022) · Cutis · doi:10.12788/cutis.0470 · Cited by 8
Werner, F., Zeschick, N., Kühlein, T., Steininger, P. A., Überla, K., Kaiser, I., Sebastião, M., Hueber, S., & Warkentin, L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03064-6 · Cited by 10
Qiao, Y., Zhan, Y., Zhang, Y., Deng, J., Chen, A., Liu, B., Zhang, Y., Pan, T. S., Zhang, W., Zhang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992062 · Cited by 8
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
Goldwater, M., Stampfer, S. D., Regidor, B. S. S., Bujarski, S. E., Jew, S. K., Chen, H., Xu, N., Kim, C. T., Kim, S., & Berenson, J. R. (2022) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2022.100214 · Cited by 10
Erythrodermic psoriasis eruption associated with SARS‐CoV ‐2 vaccination
Nia, A. M., Silva, M. M., Spaude, J., et al. (2022) · Dermatologic Therapy · doi:10.1111/dth.15380 · Cited by 8
Case Report: Retinal Vasculitis in Two Adolescents After COVID-19 Vaccination
Mohamed, S., Chan, C. K. M., Tsang, C. W., Szeto, S., Fong, A. H. C., Chan, J. C., & Wong, C. Y. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2129694 · Cited by 8
Tailoring Alkyl Side Chains of Ionizable Amino-Polyesters for Enhanced In Vivo mRNA Delivery
Espinar, A. L., Mulder, L. M., Elkhashab, M., Khan, Z., Czarnocki‐Cieciura, M., Aburto, M. R., Vučen, S. R., & Kowalski, P. S. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00116 · Cited by 8
Lombrea, A., Romanescu, M., Jianu, N., Andor, M., Suciu, M., Man, D. E., Danciu, C., Dehelean, C. A., & Buda, V. (2023) · Pharmaceuticals · doi:10.3390/ph16060853 · Cited by 8
“Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine (2020) [51] Polack, F.”
BackgroundToback, S. L., Marchese, A. M., Warren, B., Ayman, S., Zarkovic, S., Eltantawy, I., Mallory, R. M., Rousculp, M. D., Almarzooqi, F., Piechowski‐Jóźwiak, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.037 · Cited by 12
Marziali, E., Lontano, A., Regazzi, L., Paladini, A., Villani, L., Calabrò, G. E., Damiani, G., Laurenti, P., Ricciardi, W., & Cadeddu, C. (2022) · Vaccines · doi:10.3390/vaccines10111793 · Cited by 9
Nishikubo, M., Shimomura, Y., Maruoka, H., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18151 · Cited by 8
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · doi:10.1101/2021.08.13.456316 · Cited by 8
“Previous mRNA vaccine clinical trials have demonstrated onset of protective efficacy after 146 the first dose and improved protection after the boost immunization [24, 25].”
BackgroundGarcía-Cruces-Méndez, J. F., Corral-Gudino, L., Del-Amo-Merino, M. P., Eirós-Bouza, J. M., & González, M. D. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.01.011 · Cited by 9
Health Care Access and COVID-19 Vaccination in the United States: A Cross-Sectional Analysis
Guzman, C. D., Thomas, C. A., Wiwanto, L., Hu, D., Henriquez-Rivera, J. A., Gage, L., Perreault, J. C., Harris, E., Rastas, C., McCormick, D., et al. (2024) · Medical Care · doi:10.1097/mlr.0000000000002005 · Cited by 9
The solid organ transplant recipient with SARS-CoV-2 infection
Laracy, J. C., Miko, B. A., & Pereira, M. R. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000888 · Cited by 8
Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam
Nguyen, S. V., Nguyen, B. T., Duong, H., Lenh, P. T., Tran, K. T., Tran, H. M., Nguyen, T. C., Nguyen, D. P., Ta, M. N., Trieu, N. N. M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2176066 · Cited by 8
Verde, N. M. L., Riva, A., Cona, M. S., Gabrieli, A., Cattaneo, M., Fasola, C., Lipari, G., Stradis, C. D., Favorito, V., Stocchetti, B. L., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34273 · Cited by 9
Tanislav, C., Rosenbauer, J., Zingel, R., & Kostev, K. (2022) · Public Health · doi:10.1016/j.puhe.2022.03.004 · Cited by 10
Lioznov, D. A., Amosova, I. V., Sheetikov, S. A., Zornikova, K. V., Serdyuk, Y. V., Efimov, G. A., Tsyferov, M. A., Khmelevskii, M. S., Afanasiev, A., Khomyakova, N. F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278878 · Cited by 8
Scher, I., Berjohn, C. M., Byrne, C., Colombo, R. E., Colombo, C. J., Edwards, M., Ewers, E. C., Ganesan, A., Jones, M. U., Larson, D. T., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac314 · Cited by 9
Roy, S., Soteras, Í., Sheets, A., Price, R. N., Oshiro, K., Rauch, S., McPhalen, D., Nerín, M. A., Strapazzon, G., Allen, M., et al. (2021) · High Altitude Medicine & Biology · doi:10.1089/ham.2021.0032 · Cited by 9
Abbad, A., Yellin, T., Singh, G., Fried, M., Raskin, A. J., Tcheou, J., Monahan, B., Gleason, C., Andre, D., Bermúdez-González, M. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101474 · Cited by 9
Development of Venous Thromboembolism After COVID-19 mRNA-1273 Vaccine Inoculation
Mahgoub, A. E., Awuah, D., Hussain, M. S., Deliwala, S. S., Bachuwa, G. I., & Younas, M. (2022) · Cureus · doi:10.7759/cureus.22179 · Cited by 8
Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 10
Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies
Li, H., Zhang, J., Wang, K., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101303 · Cited by 8
Althaus, T., Landier, J., Zhu, F., Raps, H., Dejoux, O., Costantini, A., Lavagna, C., Rampal, P., Mattiuzzo, G., Xu, S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad030 · Cited by 8
Vaccination practices, efficacy, and safety in adults with cancer: A narrative review
Sarkar, L., Goli, V. B., Menon, N. S., Patil, V., Noronha, V., & Prabhash, K. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_156_21 · Cited by 9
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
Sheetikov, S. A., Khmelevskaya, A. A., Zornikova, K. V., Zvyagin, I. V., Shomuradova, A. S., Serdyuk, Y. V., Shakirova, N. T., Peshkova, I. O., Titov, A., Romaniuk, D. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369436 · Cited by 10
Skowronski, D., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J., Galanis, E., Naus, M., Patrick, D., Sbihi, H., Adam, S. E., et al. (2021) · medRxiv · doi:10.1101/2021.06.07.21258332 · Cited by 30
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13357 · Cited by 8
Ye, C., Qi, L., Ji, W., & Zheng, S. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.606755 · Cited by 11
Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient
Weinstock‐Guttman, B., & Jakimovski, D. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211022037 · Cited by 8
Kunc, M., Whitehead, B. J., Østergaard, L. J., Tolstrup, M., Benn, C. S., Wejse, C. M., & Nejsum, P. L. (2025) · Journal of Clinical Immunology · doi:10.1007/s10875-025-01977-w · Cited by 9
Fisher, R., Tarnovsky, Y., Hirshoren, N., Kaufman, M., & Shavit, S. S. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-07869-2 · Cited by 8
RNA-based therapeutic opportunities for the treatment of kidney diseases
Prins, J., Biscans, A., van Zonneveld, A. J., Frazier, K. S., & van der Veer, E. P. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01011-7 · Cited by 13
“The global outbreak of SARS-CoV-2 greatly accelerated the development of mRNA vaccines and gave rise to the first approved mRNA vaccines, BNT162b2 and mRNA-1273 (refs.”
Varicella‐Zoster virus reactivation following SARS‐CoV‐2 immunization in two patients with leukemia
Foster, C. E., Penella, A. D. V., Davis, A. L., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29191 · Cited by 8
Fernandes-Matano, L., Salas-Lais, Á. G., Grajales-Muñíz, C., Hernández‐Ávila, M., Garfias, Y., Rodríguez-Sepúlveda, M. C., Segura-Sánchez, C., Montes-Herrera, D., Mendoza-Sánchez, D., Ángeles-Martínez, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02376-22 · Cited by 8
Zhang, Y.-N., Paynter, J., Sou, C., Fourfouris, T., Wang, Y., Abraham, C., Ngo, T. A., Zhang, Y., He, L.-L., & Zhu, J. (2021) · bioRxiv · doi:10.1101/2021.03.26.437274 · Cited by 14
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.